JAZZ catalyst calendar

Jazz Pharmaceuticals plc

Upcoming catalysts
19
Cash runway
Cash generating
Cash & investments
$1620M
Phase 3 programs
30

Jazz Pharmaceuticals plc is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on December 21, 2026, a projected date rather than a confirmed one. There are 19 upcoming events on record.

Jazz Pharmaceuticals plc generates cash from operations, so a burn-based runway figure does not apply.

Across 171 concluded trials, 77% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
December 21, 2026 est. Next quarterly earnings (projected) Earnings —
December 31, 2026 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors Trial Milestone Phase 2
February 27, 2027 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in Healthy Male and Female Participants Trial Milestone Phase 1
August 1, 2027 Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution Trial Milestone Phase 4
November 29, 2027 A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures Trial Milestone Phase 1
November 30, 2027 JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors Trial Milestone Phase 1
December 23, 2027 A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH Trial Milestone Phase 3
January 1, 2028 A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer Trial Milestone Phase 2
January 28, 2028 Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma Trial Milestone Phase 1/Phase 2
January 31, 2028 A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC Trial Milestone Phase 2
April 1, 2028 A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 Trial Milestone Phase 1
April 28, 2028 A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Trial Milestone Phase 3
June 15, 2028 ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) Trial Milestone Phase 3
August 1, 2028 A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy Trial Milestone Phase 2/Phase 3
October 25, 2028 A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma Trial Milestone Phase 2
December 1, 2028 Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer Trial Milestone Phase 3
December 15, 2028 Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma Trial Milestone Phase 2
December 28, 2028 A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS Trial Milestone Phase 4
September 4, 2029 A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE Trial Milestone Phase 3

Track JAZZ alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open JAZZ in the tracker

Recent history

DateEventTypePhase
October 9, 2026 8-K filed: Leadership change Corporate —
September 23, 2026 8-K filed: Material agreement Corporate —
September 15, 2026 8-K filed: Reg FD disclosure Filing —
August 31, 2026 8-K filed: Material agreement, Other event Corporate —
August 25, 2026 8-K filed: Other event Filing —
August 10, 2026 8-K filed: Reg FD disclosure Filing —
August 10, 2026 8-K filed: Material agreement Corporate —
August 3, 2026 Quarterly results filed (8-K) Earnings —
July 15, 2026 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers Trial Milestone Phase 3
July 15, 2026 Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms Trial Milestone Phase 1
July 5, 2026 A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants Trial Milestone Phase 1
May 29, 2026 8-K filed: Leadership change Corporate —
May 5, 2026 Quarterly results filed (8-K) Earnings —
April 6, 2026 A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex Trial Milestone Phase 4
February 24, 2026 Quarterly results filed (8-K) Earnings —
January 29, 2026 A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1 Trial Milestone Phase 1
January 12, 2026 Quarterly results filed (8-K) Earnings —
November 17, 2025 8-K filed: Other event Filing —
November 5, 2025 Quarterly results filed (8-K) Earnings —
October 28, 2025 8-K filed: Leadership change Corporate —
October 22, 2025 8-K filed: Other event Filing —
August 30, 2025 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer Trial Milestone Phase 2
August 29, 2025 A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer Trial Milestone Phase 1/Phase 2
August 5, 2025 Quarterly results filed (8-K) Earnings —
July 10, 2025 8-K filed: Leadership change, Reg FD disclosure Corporate —
May 6, 2025 Quarterly results filed (8-K) Earnings —
April 21, 2025 8-K filed: Reg FD disclosure, Other event Filing —
March 13, 2025 A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy Trial Milestone Phase 4
February 25, 2025 A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy Trial Milestone Phase 4
January 28, 2025 Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures Trial Milestone Phase 3

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.